Details for New Drug Application (NDA): 014860
✉ Email this page to a colleague
NDA 014860 describes ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. Additional details are available on the ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE profile page.
The generic ingredient in ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is chloroquine phosphate; primaquine phosphate. There are twenty drug master file entries for this compound. Additional details are available on the chloroquine phosphate; primaquine phosphate profile page.
The generic ingredient in ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is chloroquine phosphate; primaquine phosphate. There are twenty drug master file entries for this compound. Additional details are available on the chloroquine phosphate; primaquine phosphate profile page.
Summary for 014860
| Tradename: | ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | chloroquine phosphate; primaquine phosphate |
| Patents: | 0 |
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE;EQ 45MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
